Merkel Cell Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Skin Cancer (1091)

Squamous Cell Skin Cancer (22)

Basal Cell Carcinoma (17)

Skin Cancer (1091)

Squamous Cell Skin Cancer (22)

Basal Cell Carcinoma (17)

›

No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	retifanlimab-dlwr Sensitive: A1 - Approval retifanlimab-dlwr Sensitive : A1	retifanlimab-dlwr Sensitive: A1 - Approval retifanlimab-dlwr Sensitive : A1
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	EP Sensitive: A2 - Guideline EP Sensitive : A2	EP Sensitive: A2 - Guideline EP Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2	carboplatin Sensitive: A2 - Guideline carboplatin Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	carboplatin + etoposide oral Sensitive: A2 - Guideline carboplatin + etoposide oral Sensitive : A2	carboplatin + etoposide oral Sensitive: A2 - Guideline carboplatin + etoposide oral Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2	topotecan Sensitive: A2 - Guideline topotecan Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	CAV Sensitive: A2 - Guideline CAV Sensitive : A2	CAV Sensitive: A2 - Guideline CAV Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2	talimogene laherparepvec Sensitive: A2 - Guideline talimogene laherparepvec Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	cisplatin + etoposide oral Sensitive: A2 - Guideline cisplatin + etoposide oral Sensitive : A2	cisplatin + etoposide oral Sensitive: A2 - Guideline cisplatin + etoposide oral Sensitive : A2
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	AST-008 Sensitive: B - Late Trials AST-008 Sensitive : B	AST-008 Sensitive: B - Late Trials AST-008 Sensitive : B
No biomarker	Merkel Cell Carcinoma	No biomarker	Merkel Cell Carcinoma	ITI-3000 Sensitive: B - Late Trials ITI-3000 Sensitive : B	ITI-3000 Sensitive: B - Late Trials ITI-3000 Sensitive : B
PD-L1 expression	Merkel Cell Carcinoma	PD-L1 expression	Merkel Cell Carcinoma	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
ARID2 mutation	Merkel Cell Carcinoma	ARID2 mutation	Merkel Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
NTRK1 mutation	Merkel Cell Carcinoma	NTRK1 mutation	Merkel Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-1 expression	Merkel Cell Carcinoma	PD-1 expression	Merkel Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TP53 wild-type	Merkel Cell Carcinoma	TP53 wild-type	Merkel Cell Carcinoma	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3	KRT-232 Sensitive: C3 – Early Trials KRT-232 Sensitive : C3
DLL3 expression	Merkel Cell Carcinoma	DLL3 expression	Merkel Cell Carcinoma	rovalpituzumab tesirine Sensitive: C4 – Case Studies rovalpituzumab tesirine Sensitive : C4	rovalpituzumab tesirine Sensitive: C4 – Case Studies rovalpituzumab tesirine Sensitive : C4
PD-L1 negative	Merkel Cell Carcinoma	PD-L1 negative	Merkel Cell Carcinoma	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4
NCAM1 expression	Merkel Cell Carcinoma	NCAM1 expression	Merkel Cell Carcinoma	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4	nivolumab Sensitive: C4 – Case Studies nivolumab Sensitive : C4
NKX2-1 expression	Merkel Cell Carcinoma	NKX2-1 expression	Merkel Cell Carcinoma	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4	avelumab Sensitive: C4 – Case Studies avelumab Sensitive : C4
TP53 wild-type	Merkel Cell Carcinoma	TP53 wild-type	Merkel Cell Carcinoma	RAIN-32 Sensitive: D – Preclinical RAIN-32 Sensitive : D	RAIN-32 Sensitive: D – Preclinical RAIN-32 Sensitive : D
NCAM1 expression	Merkel Cell Carcinoma	NCAM1 expression	Merkel Cell Carcinoma	McSAF 03 Sensitive: D – Preclinical McSAF 03 Sensitive : D	McSAF 03 Sensitive: D – Preclinical McSAF 03 Sensitive : D

Merkel Cell Carcinoma

Associations(28)

Associations
(28)